Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | MIP-1B | 834.0 | 29 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | MIP-1B | 59.0 | 25 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | MIP-1B | 71.5 | 28 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | MIP-1B | 1300.0 | 25 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | MIP-1B | 1866.0 | 22 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 72.0 | 34 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 65.5 | 44 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 53.5 | 58 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 62.0 | 44 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 58.5 | 32 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 67.0 | 33 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 352.0 | 47 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 186.0 | 29 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 111.0 | 25 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 80.0 | 37 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 166.0 | 30 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | MIP-1B | 123.0 | 29 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 94.0 | 37 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 97.0 | 42 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 65.5 | 44 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 71.0 | 31 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 93.0 | 44 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 86.5 | 44 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | MIP-1B | 130.5 | 32 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | MIP-1B | 162.0 | 25 |